These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20526206)

  • 1. The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial.
    Sebastian M; Reck M; Waller CF; Kortsik C; Frickhofen N; Schuler M; Fritsch H; Gaschler-Markefski B; Hanft G; Munzert G; von Pawel J
    J Thorac Oncol; 2010 Jul; 5(7):1060-7. PubMed ID: 20526206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC).
    Awad MM; Chu QS; Gandhi L; Stephenson JJ; Govindan R; Bradford DS; Bonomi PD; Ellison DM; Eaton KD; Fritsch H; Munzert G; Johnson BE; Socinski MA
    Lung Cancer; 2017 Feb; 104():126-130. PubMed ID: 28212994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer.
    Ellis PM; Chu QS; Leighl N; Laurie SA; Fritsch H; Gaschler-Markefski B; Gyorffy S; Munzert G
    Clin Lung Cancer; 2013 Jan; 14(1):19-27. PubMed ID: 22658814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer.
    Ellis PM; Leighl NB; Hirsh V; Reaume MN; Blais N; Wierzbicki R; Sadrolhefazi B; Gu Y; Liu D; Pilz K; Chu Q
    Clin Lung Cancer; 2015 Nov; 16(6):457-65. PubMed ID: 26100229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors.
    Hofheinz RD; Al-Batran SE; Hochhaus A; Jäger E; Reichardt VL; Fritsch H; Trommeshauser D; Munzert G
    Clin Cancer Res; 2010 Sep; 16(18):4666-74. PubMed ID: 20682708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia.
    Müller-Tidow C; Bug G; Lübbert M; Krämer A; Krauter J; Valent P; Nachbaur D; Berdel WE; Ottmann OG; Fritsch H; Munzert G; Garin-Chesa P; Fleischer F; Taube T; Döhner H
    Br J Haematol; 2013 Oct; 163(2):214-22. PubMed ID: 24033250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
    Bonomi PD; Mace J; Mandanas RA; Min M; Olsen M; Youssoufian H; Katz TL; Sheth G; Lee HJ
    J Thorac Oncol; 2013 Mar; 8(3):338-45. PubMed ID: 23370316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.
    Ross HJ; Blumenschein GR; Aisner J; Damjanov N; Dowlati A; Garst J; Rigas JR; Smylie M; Hassani H; Allen KE; Leopold L; Zaks TZ; Shepherd FA
    Clin Cancer Res; 2010 Mar; 16(6):1938-49. PubMed ID: 20215545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of epirubicin in combination with weekly docetaxel for patients with advanced NSCLC who have failed or relapsed after the frontline platinum-based chemotherapy.
    Lin CM; Chen CH; Chang JW; Tsao TC
    Am J Clin Oncol; 2009 Apr; 32(2):169-73. PubMed ID: 19307958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer.
    Besse B; Planchard D; Veillard AS; Taillade L; Khayat D; Ducourtieux M; Pignon JP; Lumbroso J; Lafontaine C; Mathiot C; Soria JC
    Lung Cancer; 2012 Apr; 76(1):78-83. PubMed ID: 22186627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
    Herbst RS; O'Neill VJ; Fehrenbacher L; Belani CP; Bonomi PD; Hart L; Melnyk O; Ramies D; Lin M; Sandler A
    J Clin Oncol; 2007 Oct; 25(30):4743-50. PubMed ID: 17909199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors.
    Mross K; Frost A; Steinbild S; Hedbom S; Rentschler J; Kaiser R; Rouyrre N; Trommeshauser D; Hoesl CE; Munzert G
    J Clin Oncol; 2008 Dec; 26(34):5511-7. PubMed ID: 18955456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens.
    Hainsworth JD; Cebotaru CL; Kanarev V; Ciuleanu TE; Damyanov D; Stella P; Ganchev H; Pover G; Morris C; Tzekova V
    J Thorac Oncol; 2010 Oct; 5(10):1630-6. PubMed ID: 20802351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial.
    Gridelli C; Bennouna J; de Castro J; Dingemans AM; Griesinger F; Grossi F; Rossi A; Thatcher N; Wong EK; Langer C
    Clin Lung Cancer; 2011 Nov; 12(6):407-11. PubMed ID: 21705281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study.
    Spigel DR; Waterhouse DM; Lane S; Legenne P; Bhatt K
    Clin Lung Cancer; 2013 Jul; 14(4):356-63. PubMed ID: 23391616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer.
    Oh Y; Herbst RS; Burris H; Cleverly A; Musib L; Lahn M; Bepler G
    J Clin Oncol; 2008 Mar; 26(7):1135-41. PubMed ID: 18309949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer.
    Heist RS; Fain J; Chinnasami B; Khan W; Molina JR; Sequist LV; Temel JS; Fidias P; Brainerd V; Leopold L; Lynch TJ
    J Thorac Oncol; 2010 Oct; 5(10):1637-43. PubMed ID: 20808253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase II study.
    Kubota K; Niho S; Enatsu S; Nambu Y; Nishiwaki Y; Saijo N; Fukuoka M
    J Thorac Oncol; 2009 Dec; 4(12):1530-6. PubMed ID: 19755925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity.
    Rudolph D; Steegmaier M; Hoffmann M; Grauert M; Baum A; Quant J; Haslinger C; Garin-Chesa P; Adolf GR
    Clin Cancer Res; 2009 May; 15(9):3094-102. PubMed ID: 19383823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.